1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells

Zhirong Jia, Yameng Zhang, Aiwen Yan, Meisa Wang, Qiushuang Han, Kaiwei Wang, Jie Wang, Chen Qiao, Zhenzhen Pan, Chuansheng Chen, Dong Hu and Xuansheng Ding

Abstract
Recent studies have demonstrated that acquisition of cancer stem-like properties plays an essential role in promoting epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) resistance in non-small cell lung cancer (NSCLC); however, how to regulate cancer stem-like properties and EGFR-TKI resistance is largely unclear. In this study, we discovered that increased iroquois-class homeodomain protein 4 (IRX4) was related to gefitinib resistance in NSCLC cells. Knockdown of IRX4 inhibited cell proliferation, sphere formation, and the expression of CD133, ALDH1A1, NANOG, Sox2 and Notch1, and the transcriptional activity of NANOG promoter. IRX4 overexpression increased the protein level of NANOG and CD133 in PC-9 cells. Combination of knocking-down IRX4 with gefitinib increased cell apoptosis and decreased cell viability and the expression of p-EGFR and NANOG in PC-9/GR cells. IRX4 knockdown in a PC-9/GR xenograft tumor model inhibited tumor progression and the expression of NANOG and CD133 more effectively than single treatment alone. Knockdown of NANOG inhibited the expression of CD133 and restored gefitinib cytotoxicity, and NANOG overexpression-induced cancer stem-like properties and gefitinib resistance could be obviously reversed by knocking-down IRX4. Further, we found that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) reduced obviously the expression of IRX4 and NANOG by inhibiting the activation of TGF-β1/Smad3 signaling pathway; moreover, combination of 1,25(OH)2D3 and gefitinib decreased cell viability and proliferation or tumor progression and the expression of IRX4 and NANOG compared with single treatment alone both in PC-9/GR cells and in a PC-9/GR xenograft tumor model. These results reveal that inhibition of IRX4-mediated cancer stem-like properties by regulating 1,25(OH)2D3 signaling may increase gefitinib cytotoxicity. Combination therapy of gefitinib and 1,25(OH)2D3 by targeting IRX4 and NANOG, could provide a promising strategy to improve gefitinib cytotoxicity.

Introduction
Lung cancer has been noted due to the increasing rate of morbidity and mortality worldwide. Many patients with lung adenocarcinoma (LUAD), a major subtype of lung cancer, harbor mutations in the epidermal growth factor receptor (EGFR) in their cancer tissues and initially react well to molecular targeted drugs such as gefitinib, which inhibits the EGFR-tyrosine kinase. However, acquired drug resistance inevitably occurs within...
10–14 months, leading to poor prognosis. Several mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have been elucidated, mainly including the mutation of EGFR T790M, MET and HER2 amplification. Whereas, underlying resistance mechanism remains undefined in a significant percentage of patients. Therefore, it is of great significance to investigate potential mechanisms and alternative strategies for reversing gefitinib resistance or enhancing its efficacy.

Growing evidence revealed that stem cell-like properties were involved in EGFR-TKI resistance. Non-small cell lung cancer (NSCLC) cells developed cancer stem cell-like properties after acquiring resistance to afatinib. In addition, the delayed development of cancer stem-like cells was accompanied with reduced tumor burden and improved recurrence free survival as well as overall survival in xenograft models of EGFR-mutant NSCLC cells. Further, acquisition of stemness phenotype after the emergence of EGFR-TKI resistance enhanced tumor metastasis in lung cancer. Consequently, during a long-term exposure to TKIs, the appearance and enrichment of cancer stem-like cells may be one of the causes for acquired resistance. Nevertheless, how to regulate the stem-like properties deserves further study.

Iroquois-class homeodomain protein 4 (IRX4) is a protein that in humans is encoded by the IRX4 gene. The analysis showed upregulated expression of IRX4 in lung tissues of NSCLC patients and a negative association between IRX4 expression and survival rate of NSCLC patients. Further, genome-wide identification of NSCLC patients suggested that IRX4, functioning as a carcinogenic transcription factor, was positively correlated with cell proliferation. Despite these advances, the role of IRX4 in NSCLC as well as in EGFR-TKI resistance remains largely unknown.

The IRX-family genes participate in the development of embryonic tissues in a variety of modes by encoding IRX proteins, and appear to play different roles at different stages of the embryo. Studies have shown that IRX4 mouse embryonic cells have multi-directional differentiation potential and high proliferative capacity, and IRX4a regulates the expression of the sox2 gene, both in the neural plate and in progenitor cells of the lateral line system. This indicates that IRX4-positive cells have differentiation potential and characteristics of stem-like cell. However, whether IRX4 regulate the cancer stem-like properties of EGFR-TKI resistant cells needs further study.

Pre-clinical models support the idea that the active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) inhibits lung cancer growth. Note of NSCLC cells with an EGFR mutation also respond well to 1,25(OH)2D3/erlotinib combination increased erlotinib cytotoxicity in both the erlotinib-sensitive HCC827 cell line and the erlotinib-resistant H1975 cell line. However, how 1,25(OH)2D3 regulate EGFR-TKI sensitivity is unknown. It has been reported that 1,25(OH)2D3 inhibited cancer cell stemness. This led us to speculate that 1,25(OH)2D3 may inhibit EGFR-TKI resistance by reducing cancer cell stemness. In this study, the role of IRX4 in regulating EGFR-TKI resistance and cancer stem-like properties, and the effects of 1,25(OH)2D3 on regulating IRX4-mediated cancer cell stemness and EGFR-TKI resistance, were investigated.

Results

IRX4 expression is upregulated by gefitinib exposure

We found that IRX4 was widely expressed in LUAD cells, IRX4 expression was significantly higher in PC-9/GR cells than that in PC-9 cells, and was also obviously higher in H1975 cells than that in HCC827 cells. The paired high (PC-9/GR) and low (PC-9) IRX4-expressing cell lines were used for further studies. The detection of IC50 values against gefitinib and colony formation confirmed that PC-9 was gefitinib-sensitive and PC-9/GR was gefitinib-resistant. The upregulation of IRX4 in PC-9/GR cells was confirmed by QRT-PCR and western blotting, however, the mRNA levels of IRX-family members such as IRX3 and IRX5 had no significant change (Fig. 1a, b). The IRX4 was mainly expressed in the nucleus and the nuclear expression of IRX4 was higher in PC-9/GR cells than that in PC-9 cells (Fig. 1c, d), indicating IRX4 functions in the nucleus. Then, a rapid method inducing gefitinib-resistant PC-9 cells (PC-9-GR) was established (Fig. 1e). The changing cell morphology was recorded at indicated time points (Fig. 1f). The IRX4 expression was gradually increasing with the prolongation of gefitinib exposure (Fig. 1k). IC50 values against gefitinib of PC-9/GR cells was about 20 μM (Fig. 1l), and IRX4 expression in PC-9-GR cells was obviously elevated than in PC-9 cells (Fig. 1m).

Downregulation of IRX4 expression enhances the gefitinib cytotoxicity of PC-9/GR cells

As the results shown, IRX4 silence (Fig. 2a, b) prominently inhibited the colony formation of PC-9/GR cells (Fig. 2c), and led to cell cycle arrest at S phase (Fig. 2d). The detection of cell viability and apoptosis indicated that the combination of knocking-down IRX4 and gefitinib was more sensitive to gefitinib than the single treatment group (Fig. 2e, f). Furthermore, we found that combination group further reduced the expression of p-EGFR compared with the single treatment (Fig. 2g).

Knocking-down IRX4 decreases NANOG expression and stemness of PC-9/GR cells

Next, lentivirus-ShRNA-IRX4 carrying enhanced green fluorescent protein (ZsGreen) was generated, and the best
infection conditions were determined. Both the group of shNC and shIRX4 had the similar infection efficiency (Fig. 3a), and the IRX4 expression was effectively knocked-down (Fig. 3b). IRX4 knockdown in PC-9/GR cells significantly inhibited sphere formation (Fig. 3c) and reduced the percentage of CD133^+ cells (Fig. 3d). Moreover, IRX4 knockdown downregulated mRNA levels of stemness-related genes (NANOG, Notch1 and CTNNB1).
suppressed tumor progression compared with any single and CD133 expression (Fig. 4a), and cell viability (Fig. 4b) Of IRX4 and ge

In vivo antitumor activity of combined knocking-down IRX4 and ge

1,25(OH)2D3 (1,25D) reduces IRX4 and NANOG expression by inhibiting TGF-β1/Smad3 signaling pathway

1,25D downregulated the transcript and protein of IRX4, increased the VDR expression and reduced NANOG expression (Fig. 6a, b). However, gefitinib treatment alone did not significantly change the expression of IRX4 and NANOG, and high dose of gefitinib reduced obviously VDR expression (Fig. 6c). TGF-β1 induced the production of CD44+CD133+ PC-9/GR cells (Fig. 6d) and increased the expression of CD133 and MDR1 both in PC-9 and PC-9/GR cells (Fig. 6e), moreover, TGF-β1 increased the transcript and protein of IRX4 and NANOG in a time-dependent manner (Fig. 6f–h). TGF-β1 activated Smad3 signaling pathway (Fig. 6i) and the inhibition of TGF-β1/Smad3 signaling with SIS3 reduced obviously the expression of IRX4 and NANOG (Fig. 6j). 1,25D inhibited the activation of Smad3 signaling (Fig. 6k), and the expression of IRX4 and NANOG induced by TGF-β1 in a dose-dependent manner (Fig. 6l).

1,25D/gefitinib combination results in increased growth suppression of PC-9/GR cells

In contrast with gefitinib or 1,25D treatment alone, combined treatment significantly decreased the IC50 value against gefitinib, number of colonies, cells

NANOG mediates the regulation of IRX4 on cancer stem-like properties and gefitinib resistance

We found that BBI503 (Amcasertib), which is a small-molecule multi-kinase inhibitor, inhibited the NANOG and CD133 expression (Fig. 4a), and cell viability (Fig. 4b) in PC-9/GR cells. Moreover, the combination of BBI503 with various concentration of gefitinib decreased the cell viability significantly (Fig. 4c). By silencing NANOG, the expression of NANOG and CD133 in PC-9/GR cells was also reduced (Fig. 4d). Additionally, NANOG silence inhibited colony formation (Fig. 4e) and cell viability of PC-9/GR cells (Fig. 4f). NANOG silence combined with gefitinib significantly decreased the cell viability compared with gefitinib alone (Fig. 4g). Furthermore, increase of NANOG and CD133 expression, and gefitinib resistance induced by NANOG overexpression could be reversed by knocking-down IRX4 (Fig. 4h, i).

In vivo antitumor activity of combined knocking-down IRX4 and gefitinib therapy

The establishment of the xenograft mice model was illustrated as shown in the figure (Fig. 5a). As expected, the combination of shIRX4 and gefitinib significantly suppressed tumor progression compared with any single treatment (Fig. 5b–d). Moreover, downregulation of IRX4 inhibited the expression of NANOG and CD133, and combination of knocking-down IRX4 and gefitinib further decreased significantly the expression of IRX4, NANOG and CD133 compared with administrating gefitinib alone (Fig. 5e). The effects of IRX4 downregulation increasing gefitinib cytotoxicity and inhibiting cancer stem-like properties are well demonstrated in a PC-9/GR xenograft mouse model.
Fig. 2 (See legend on next page.)
proliferation rate (Fig. 7a–c). Moreover, the expression of VDR was obviously upregulated and the expression of IRX4 and NANOG was significantly downregulated in the combined treatment group than in the gefitinib alone treatment group (Fig. 7d).

1,25D/gefitinib combination results in increased growth suppression in vivo

Tumors treated with 1,25D and gefitinib alone inhibited tumor progression relative to tumors treated with the vehicle, and treatment with the combination of the two agents significantly suppressed tumor progression compared with one agent alone (Fig. 8a–c). 1,25D treatment obviously decreased the expression of IRX4 and NANOG, and the combined 1,25D and gefitinib treatment clearly reduced IRX4 and NANOG expression compared to gefitinib or 1,25D treatment alone (Fig. 8d). The in vivo results confirm that 1,25D synergizes with gefitinib to inhibit xenograft growth, consistent with the in vitro results.

Discussion

In this study, we investigated the relationship between IRX4 and gefitinib resistance in NSCLC cell lines, which has not been reported. The results showed that IRX4 expression in PC-9/GR cells with acquired resistance to gefitinib was evidently upregulated compared with that in gefitinib-sensitive PC-9 cells. Moreover, IRX4 expression in H1975 cells with primary resistance to gefitinib was also higher than that in gefitinib-sensitive HCC827 cells. Of note, IRX4 expression has been increasing during the process of PC-9 cells exposing to gefitinib. Next, by silencing IRX4 in PC-9/GR cells, we observed that downregulation of IRX4 inhibited cell viability and the combination of knocking-down IRX4 with gefitinib further decreased cell viability and the level of p-EGFR compared with the single treatment. Our results provide evidence that inhibition of IRX4 expression increases gefitinib cytotoxicity.

How IRX4 controls gefitinib cytotoxicity? Several research groups have observed stem cell-like features, including overexpression of putative stem cell markers ALDH1A1, ABCB1, NANOG, and Sox2 in cells with acquired resistance to gefitinib, afatinib or osimertinib. Furthermore, when the stem cell-like characteristics of gefitinib-resistant cells were lost, gefitinib sensitivity regained. These studies have prompted us to investigate whether inhibition of IRX4 expression may increase gefitinib cytotoxicity through regulating stem cell-like properties. We first found that IRX4 knockdown significantly downregulated the pulmosphere forming ability, the percentage of CD133 positive population, and NANOG, Notch1, Sox2, ALDH1A1, ABCB1, and CD133 expression in PC-9/GR cells. Moreover, IRX4 overexpression in PC-9 cells obviously enhanced protein levels of NANOG, CD133 and MDR1. Considering the significant effect of IRX4 regulating NANOG, the Luciferase Reporter Assay was performed, and the results showed that IRX4 could regulate the transcription of NANOG. Further, combined use of gefitinib and IRX4 knockdown significantly downregulated NANOG protein level in vitro, and markedly decreased tumor growth and the expression of NANOG and CD133 in vivo, than treatment with gefitinib alone.

NANOG is a master transcription factor that regulates stem cell pluripotency and cellular reprogramming. RNAi-mediated NANOG knockdown leads to attenuated cancer stem cell (CSC) properties such as sphere formation and clonogenic efficiency in breast and prostate cancer cells. Of note, the protein level of NANOG in lung cancer tissues was upregulated compared to the normal lung tissues and NANOG overexpression predicted a worse prognosis for lung cancer patients. Despite the importance of NANOG in lung cancer progression and in regulating CSC properties, the relevance between NANOG with EGFR-TKI resistance is yet unclear. In the current study, the effect of NANOG on regulating gefitinib resistance in PC-9/GR cells was
determined by inhibiting NANOG expression via using BBI503 or transfecting siRNA. Results from the experiments showed that decrease of NANOG inhibited CD133 expression and cell proliferation, and enhanced gefitinib cytotoxicity. Our results, together with those previous studies, showed that NANOG was associated with

**Fig. 3** (See legend on next page.)
stems-like properties, further indicated that inhibition of NANOG-mediated stem cell-like properties enhanced gefitinib cytotoxicity. Of note, NANOG overexpression-induced cancer stem-like properties and gefitinib resistance could be obviously reversed by knocking-down IRX4. The above results suggest that the regulation of IRX4 on cancer stem-like properties and gefitinib resistance was mediated by NANOG.

How to regulate IRX4-mediated cancer stem-like properties and gefitinib resistance? 1,25(OH)2D3/VDR signaling pathway restrains cancer stem cell-like properties19,25. Based on the observations that inhibition of IRX4 decreased NANOG-mediated cancer stemness, we examined the relationship between 1,25(OH)2D3/VDR and IRX4-induced NANOG expression. We uncovered that 1,25(OH)2D3 reduced significantly the expression of IRX4 and NANOG. Conversely, gefitinib alone did not exert obvious effect on the IRX4 and NANOG expression. However, when gefitinib was combined with 1,25 (OH)2D3, its ability to decrease IRX4 and NANOG expression was increased. The association between 1,25 (OH)2D3 and TGF-β/Smad signaling pathway28,29 led us to consider whether TGF-β/Smad signaling pathway induces the IRX4-induced cancer stem-like properties. Studies have shown that TGF-β1 signaling promotes cancer cell stemness, leading to tumor metastasis30,31. Whether TGF-β1 increased cancer cell stemness by regulating IRX4 and how to regulate TGF-β1 signaling mediated cancer stem-like properties is unclear. In this study, we discovered that TGF-β1/Smad3 signaling increased IRX4 expression and NANOG-mediated cancer cell stemness. Notably, high TGF-β1 levels were correlated with poor EGFR-TKI sensitivity and overall survival in NSCLC samples. Moreover, TGF-β1 could increase EGFR-TKI resistance in PC-9 cancer cells32 and in A549 cells33. Therefore, we speculate that TGF-β1 may increase EGFR-TKI resistance by regulating IRX4-induced cancer stem-like properties. Next, whether 1,25(OH)2D3 regulates the TGF-β1/Smad signaling-induced IRX4 and NANOG expression or is simply correlated with it, was determined. The results demonstrated that 1,25(OH)2D3 inhibited the activation of Smad3, and the ability of TGF-β1 to induce IRX4 and NANOG expression was attenuated by 1,25(OH)2D3. Furthermore, we discovered that, both in vitro and in vivo, combination of 1,25(OH)2D3 with gefitinib resulted in significant growth inhibition of PC-9/GR cells, and combination treatment further decreased the expression of IRX4 and NANOG compared with single treatment. In light of our new data, we conclude that, 1,25(OH)2D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in PC-9/GR cells.

In summary, the roles of IRX4 downregulation increasing gefitinib cytotoxicity and inhibiting NANOG-mediated cancer stem-like properties were elucidated for the first time, to the best of our knowledge. Furthermore, collective efforts have been done to explore how to regulate IRX4 and NANOG expression and to find new strategies overcoming gefitinib resistance, such as, combination of gefitinib with 1,25(OH)2D3. Our study provides a new strategy through targeting IRX4 to enhance gefitinib cytotoxicity.

Materials and methods

Cell lines

NSCLC lines PC-9 and PC-9/GR (The gifts from Nanjing Medical University), A549 (ATCC® CCL-185™, ATCC, Manassas, VA, USA), HCC827 (ATCC® CRL-2868™), H1975 (ATCC® CRL-5908™), H1650 (ATCC® CRL-5883™) and H23 (ATCC® CRL-5800™) were cultured in Dulbecco modified Eagle medium (DMEM) (Biological Industries, Kibbutz Beit-Haemek, Israel) or...
Fig. 4 NANOG mediates the regulation of IRX4 on cancer stem-like properties and gefitinib resistance. 

a PC-9/GR cells were exposed to BBI503 (0.1 and 1 μmol/L) for 48 h and then harvested for western blotting to detect the NANOG and CD133 expression. 
b Treatment with BBI503 at indicated concentrations for 48 hours suppressed the growth of PC-9/GR cells in a dose-dependent manner. ***P < 0.001, ****P < 0.0001. 
c Effect of combined treatment with BBI503 (0.1 μM) and gefitinib on growth of PC-9/GR cells was evaluated, and the IC50 against gefitinib was calculated (mean ± SD, n = 3; ***P < 0.001). 
d PC-9/GR cells were transfected with NANOG siRNA (siNANOG) or control siRNA (siCtrl). Total cell lysate proteins were extracted for western blot analysis of NANOG and CD133 expression using specific antibodies. 
e–f The detection of clonal formation and cell viability after silencing NANOG expression (mean ± SD; n = 3; ***P < 0.001). 
g–h PC-9/GR cells were transfected with siNANOG or siCtrl, after 6 h, the cells were exposed to various concentrations of gefitinib (0, 6.25, 12.5, 25, 50 μM) for another 48 h. Cell proliferation was determined by MTT assay, and the IC50 against gefitinib was calculated. Data represent the mean ± SD of three replicate determinations, ***P < 0.001. 
h PC-9/GR cells were infected with lentivirus carrying shIRX4 or shNC for 24 h, and then NANOG was overexpressed by transfecting with the pcDNA3.1-NANOG plasmid or the empty vector (pcDNA3.1) for another 48 h. Cell proliferation was determined by CCK8 assay, and the IC50 against gefitinib was calculated. Data represent the mean ± SD of three replicate determinations, ***P < 0.001, ****P < 0.0001.
RPMI 1640 (Biological Industries) supplemented with 10% fetal bovine serum (FBS) (Biological Industries), 100 μg/mL streptomycin and 100 U/mL penicillin (Key-GEN BioTECH, Nanjing, China) in a humidified cell incubator at 37 °C with an atmosphere of 5% CO2.

Reagents and chemicals
The reagents used in this study were purchased as follows. Primers were ordered from Genscript (Nanjing, China). Gefitinib, BBI503, SIS3, and 1,25(OH)2D3 (calciotriol) were purchased from selleck (Shanghai, China). TGF-β1, EGF and FGF-basic were obtained from PeproTech (Rocky Hill, NJ, USA). B27 was obtained from Gibco (Gaithersburg, MD, USA).

Western blot analysis
Proteins were extracted from the NSCLC cells (n = 3, biological replicates) or tumor tissues in the lysis buffer (KeyGEN BioTECH, Nanjing, China) and protease inhibitor cocktail (KeyGEN BioTECH, Nanjing, China) for western blotting. Antibodies used for western blotting were: anti-IRX4 (ab123542, Abcam, Cambridge, UK), anti-pEGFR, EGFR, p-smad3, smad2/3 (#3777, #4267, #9520, #8685, Cell Signaling Technology, Boston, MA, USA), anti-CD133, NANOG, Notch1, β-catenin, MDR1, VDR, ABCG2 and anti-Histone-H3 (18470-1-AP, 14295-1-AP, 51067-2-AP, 22336-1-AP, 14526-1-AP, 27286-1-AP, 17168-1-AP, Proteintech group, WUHAN SANYING, WuHan, China), anti-Sox2, Oct4, ALDH1A1 (D164316, D121072, D220058, Sangon Biotech, Shanghai, China), and anti-β-actin, anti-GAPDH (bs-0061R, bs-0755R, Bioss, Beijing, China) antibodies, HRP-conjugated goat anti-rabbit IgG secondary antibody (ABL3012-2, AbSci, Vancouver, WA, USA). The electrochemical luminescent substrates (Tanon, Shanghai, China) were used according to the manufacturer’s protocol in order to visualize the proteins of interesting in the Tanon imaging.
system. The relative expressions were quantified densitometrically using the ChemiScope analysis software and calculated according to the reference bands of GAPDH or β-actin.

Quantitative real-time PCR

Total RNA was extracted from NSCLC cells using Trizol reagent (Vazyme, Nanjing, China) as described by the manufacturer before cDNA synthesis (Vazyme,
Nanjing, China) (n = 3, biological replicates). The level of GAPDH RNA expression was used to normalize the data. The mRNA primer sequences (GenScript, Nanjing, China) used for QRT-PCR were human IRX4: 5′-CCTTC TACTCGCTGAACA-3′ (forward, F), 5′-TGGCTCGTAA GGGTAGTA-3′ (reverse, R); human NANOG: 5′-CTCCA ACAT CCTGAACCT-3′ (F), 5′-GTCACAC CATTGCT ATTCTT-3′ (R); human CTNNB1: 5′-CAAGCCACAAG ATTACAAGA-3′ (F), 5′-CACCAATATCAAGTCCAAG AT-3′ (R); human Notch1: 5′-GGACCTCATCAACTCA CA-3′ (F), 5′-TTCTTCAGGAGC ACACT-3′ (R); human IRX3: 5′-CTGTAGTGGCTTGGAAATG-3′(F), 5′-GGAG AG AGCCGATAAGC-3′ (R); human IRX5: 5′-CTCTCGAGGTACCTGCTGG-3′(F), 5′-AATGACGCTGTT GCTGTACG -3′ (R); human GAPDH: 5′-CTTCTTTTG CGTC GCCAGCCGA-3′(F), 5′-ACCAGGGCAGCGCAAT ACGACGCAA-3′ (R); Primers were used to quantify expression with RT-PCR (Applied Biosystems, Foster City, CA, USA) and results were analyzed with the ΔΔCt method.

**Cell viability assays and Edu staining**

The cell viability assay was performed as previously described. Briefly, 2 × 10^3 cells/well was seeded in 96-well plates (n = 6 per group, n = 3, biological replicates). Twenty-four hours after seeding, the cells were
transfected with siRNA, or treated with various concentrations of gefitinib or gefitinib + 1,25(OH)2D3 in medium containing 10% FBS for 48 h. Absorbance was measured at indicated time points. Cell proliferation was quantified based on the incorporation of 5-ethynyl-2'-deoxyuridine (Edu) into DNA using a BeyoClick™ EdU-594 In Vitro Imaging Kit (Beyotime, Nantong, China) as previously described36. A laser scanning confocal microscope (Carl Zeiss, Jena, Germany) was used to determine the proportion of nucleated cells that had incorporated Edu. The assay was performed in triplicate and repeated three times in independent experiments.

Cell HE staining
The cells were seeded in 6-well plates. Twenty-four hours after seeding, the cells were washed by PBS for three times and fixed with methanol for 5 min, and then stained with hematoxylin and eosin (n = 2, biological replicates). The cell morphology was recorded by microscopy (Olympus, Tokyo, Japan).

siRNA and plasmid transfection
In all experiments, 150 pmol siRNA (the target sequence of IRX4-specific siRNA: 5'-GGAAAUGUCUCAUUAGUUTT-3' or NANOG-specific siRNA: 5'-GGA GGUCUAUUUCUCUAATT-3') (TranSheep Bio, Shanghai, China) or 5 μg of pcDNA3.1-IRX4 or pcDNA3.1-NANOG or empty vector (HanBio, Shanghai, China) were used to transfect 70–80% confluent cells according to the manufacturer’s instructions (n = 3, biological replicates). The Lipofectamine 2000 reagent (Life Technologies, Carlsbad, CA, USA) was used to deliver siRNA or plasmid into PC-9/GR or PC-9 cells growing in serum-free opti-MEM media (Gibco, Gaithersburg, MD, USA). After 6 h, the medium containing the siRNA/plasmid-lipid complexes was replaced with DMEM containing 10% FBS. And subsequent experiments were completed at indicated time after transfection.

Luciferase reporter assay
pGL3-NANOG-luc (pNANOG-luc) was obtained from HanBio (Shanghai, China). The reporter constructs containing 2331 bp (-2309 to 22) of NANOG promoter. PC-9/GR cells were transfected with the siRNA targeting IRX4 or negative control and the pNANOG-luc plasmid, and the pRL-TK was co-transfected in each experiment as an internal control for transfection efficiency. At 48 h post-transfection, cells were lysed and the luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Vazyme, Nanjing, China) and a
Multifunctional microplate reader (Molecular Devices ID5, Sunnyvale, CA, USA). The firefly luciferase activity was corrected by the corresponding Renilla luciferase activity and the experiments were carried out in triplicate.

Colony-formation assay
The cells were stimulated with various concentration of gefitinib or transfected with siCtrl or siIRX4 or siNANOG. After approximately 14 days of culturing, the colonies were fixed in methanol and stained with 0.1% crystal violet (KeyGEN BioTECH, Nanjing, China). Colonies with a diameter greater than 1 mm were counted. Samples were assayed in triplicate.

Lentivirus infection
1.5 × 10^5 PC-9/GR cells were seeded in 6-well plates. Twenty-four hours after seeding, the cells were treated with polybreen (5 μg/mL) and respectively infected with various volume of lentivirus (4 × 10^8TU/mL) carrying shNC or shIRX4 (HanBio, Shanghai, China). After 72 h, the cells were collected, and ZsGreen positive cells were analyzed by flow cytometry (Miltenyi Biotec, Cologne, Germany) (n = 2, biological replicates) and FlowJo VX software, and the expression of IRX4, NANOG, Sox2, Oct4, ABCG2, and ALDH1A1 was evaluated by western blotting (n = 3, biological replicates).

Flow cytometry
The experiment was performed as methods described previously. Briefly, 1 × 10^6 cells was washed twice with PBS supplemented with 0.5% BSA and 2 mM EDTA and incubated with 5 μL each of anti-CD133-PE (TMP4 clone; eBioscience, Waltham, MA, USA) or anti-CD44-FITC (BJ18 clone; BioLegend, San Diego, CA, USA) antibodies diluted in 100 μL of staining solution for 15 min at room temperature. Then, after washing the cells twice, 400 μL of buffer was added, and samples were analyzed by flow cytometry (Miltenyi Biotec) and FlowJo VX software (n = 3, biological replicates).

Xenografts assay
Four-week-old male BALB/c nude mice were obtained from Cavens Experimental Animal Co., Ltd (Changzhou, China). All experiments involving animals were approved by the Ethics Committee of China Pharmaceutical University. The animals were maintained in individual ventilated cages in compliance with institutional guidelines. The xenograft model was established as methods described previously. Briefly, the PC-9/GR cells were respectively infected with a lentivirus carrying control shRNA (shNC) or with shIRX4 (Contract number HH20190622LHY-LV03, HanBio, Shanghai, China). After 3 days, the cells were harvested and resuspended respectively, then approximately 1.5 × 10^7 cells were subcutaneously injected into the right forelimb of mice. The mice of shNC and shIRX4 group were randomized into four groups (n = 8 per group), and when tumor volume reaches an average of 80mm^3, the mice were treated with gefitinib (50 mg/kg) or drinking water (vehicle) alone. In addition, another xenograft mouse model was established, and the effect of 1,25(OH)2D3 combined with gefitinib was evaluated. Briefly, approximately 1 × 10^7 PC-9/GR cells were subcutaneously injected into the right forelimb of mice. Treatment began 1 week following injection. The mice were randomized into four groups (n = 8 per group) and intragastric administrated with vehicle (PBS), 1,25(OH)2D3 (1 μg/kg/2day), gefitinib (50 mg/kg/day) or 1,25(OH)2D3 (1 μg/kg/2day) + gefitinib (50 mg/kg/day). The tumor volume was measured once every two days and calculated as (length×width^2)/2. The animals were monitored for approximately 3 weeks until euthanasia. Mice died before being sacrificed were excluded, and the xenografts from each group were collected for further analyses. No blinding was carried out for animal experiments.

Statistical analysis
Data were expressed as mean values ± Standard Deviation. Power analysis was performed to choose the sample size. Two-sided statistical tests were performed. Unpaired Student’s t test was used when comparing two groups. One-way ANOVA with Dunnett’s test or two-way ANOVA with Bonferroni’s multiple comparison was used to compare multiple groups. Statistical analysis was performed using Prism 8.00 software (GraphPad, San Diego, CA, USA). The differences were considered significant for P < 0.05.

Acknowledgements
This work was supported by the National Natural Science Foundation of China (81873131). We thank molecular Experiment Platform of State Key Laboratory of Natural Medicines at China Pharmaceutical University for providing Flow Cytometry. We also thank Dr. Yong Xu of Jiangsu Cancer Hospital for his suggestions for improving the experiments.

Author details
1School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 211198 Nanjing, China. 2Department of Pharmacy, the First Affiliated Hospital of Xinxjiang Medical University, 830054 Urumqi, China. 3Precision Medicine Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 211198 Nanjing, China. 4Key Laboratory of Industrial Dust Prevention and Control & Occupational Safety and Health of the Ministry of Education, Medical School, Anhui University of Science and Technology, 232001 Huainan, China

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
1. Allemani, C. et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023–1075 (2018).
2. Li, T., Kung, H. J., Mack, P. C. & Gandara, D. R. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J. Clin. Oncol. 31, 1039–1049 (2013).
3. Ettinger, D. S. et al. NCCN guidelines insights: non-small cell lung cancer, Version 5.2018. J Natl Compr. Canc Netw. 16, 807–821 (2018).
4. Lee, S. H. et al. A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cells. Cell Death Dis. 5, e1477 (2014).
5. Rocco, D., Battiloro, C., Gravara, L. D. & Giddelli, C. Advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation: first-line treatment and beyond. Rev. Recent Clin. Trials 14, 120–128 (2019).
6. Shah, R. R. & Shah, D. R. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 42, 181–198 (2019).
7. Asoa, T., Takahashi, F. & Takahashi, K. Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respir. Invest. 57, 20–26 (2019).
8. Hashida, S. et al. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to gefitinib. Cancer Sci. 106, 1377–1384 (2015).
9. Aroasa, R. R. et al. Notch3-dependent beta-catenin signaling mediates EGRF TKI drug persistence in EGFR mutant NSCLC. Nat. Commun. 9, 3198 (2018).
10. Zhang, F. et al. CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer. Clin. Exp. Metastasis 36, 229–243 (2019).
11. Shen, K. et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 73, 3051–3061 (2013).
12. Zhang, D. L. et al. Genome-wide identification of transcription factors that are critical to non-small cell lung cancer. Cancer Lett. 343, 155–163 (2015).
13. Cardena-Nunez, S. et al. Expression patterns of Ikh genes in the developing chick inner ear. Brain Struct. Funct. 222, 2071–2092 (2017).
14. Tena, J. J. et al. An evolutionarily conserved three-dimensional structure in the vertebrate Ikh clusters facilitates enhancer sharing and coregulation. Nat. Commun. 2, 310 (2011).
15. Nelson, D. O. et al. Ikh marks a multipotent, ventricular-specific progenitor cell. Stem Cells 34, 2875–2888 (2016).
16. Feijo, C. G., Saldias, M. P., De la Paz, J. F., Gomez-Skarmeta, J. L. & Allende, M. L. Formation of posterior cranial placode derivatives requires the Iroquois transtion factor irx4a. J. Exp. Zool. 267, 340–347 (2009).
17. Horton, R. & O’Connell, M. A. Vitamin D. potential in the prevention and treatment of lung cancer. Anticancer Res. 32, 211–221 (2012).
18. Zhang, Q. et al. Differential response to 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations. J. Steroid Biochem Mol. Biol. 136, 264–270 (2013).
19. Ji, M., Liu, L., Hou, Y. & Li, B. 1alpha,25-Dihydroxyvitamin D3 restrains stem cell-like properties of ovarian cancer cells by enhancing vitamin D receptor and suppressing CD44. Oncol. Rep. 41, 3393–3403 (2019).
20. Saygin, C., Matei, D., Majeti, R., Rezies, O. & Lathia, J. D. Targeting cancer stemness in the clinic: hype to hope. Cell Stem Cell 24, 25–40 (2019).
21. Li, L. et al. Protective autophagy decreases cismitinib cytotoxicity through regulation of stem cell-like properties in lung cancer. Cancer Lett. 452, 191–202 (2019).
22. Nishimura, T. et al. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. Oncogene 38, 2496–2481 (2019).
23. Liu, Y. N. et al. IGF-confluent resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget 6, 10415–10431 (2015).
24. Jeter, C. R. et al. Functional evidence that the self-renewal gene NANG regulates human tumor development. Stem Cells 27, 993–1005 (2009).
25. Matheiu, J. et al. HF induces human embryonic stem cell markers in cancer cells. Cancer Res. 71, 4640–4652 (2011).
26. Di, Y. et al. Nanog, a novel prognostic marker for lung cancer. Surg. Oncol. 22, 224–229 (2013).
27. Li, Z. et al. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Clin. Cancer Res. 21, 844–853 (2015).
28. Xu, S. et al. Calticin inhibits migration and invasion of renal cell carcinoma cells by suppressing Smad2/5, STAT3- and beta-catenin-mediated epithelial-mesenchymal transition. Cancer Sci. 111, 59–71 (2020).
29. Zhou, Q. et al. LQH23 induces regulatory T cell differentiation by influencing the VDR/PLC-gamma1/7TPA-beta1pathway. Mol. Immunol. 91, 156–164 (2017).
30. Yeh, H. W. et al. PSCP1 mediates TGF-beta1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis. Nat. Cell Biol. 20, 479–491 (2018).
31. Wu, L. et al. TGF-beta1-induced PK17 enhances cancer stem cell-like properties rather than EMT in promoting cervical cancer metastasis via the ERK1/2-MZF1 signaling pathway. FEBS J. 284, 3000–3017 (2017).
32. Shen, H. et al. TGF-beta1 induces efotinib resistance in non-small cell lung cancer by down-regulating PTEN. Biomed. Pharmacother. 77, 1–6 (2016).
33. Kitanuma, K. et al. MiR-134/487b/655 cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAG2 in lung adenocarcinoma cells. Mol. Cancer Ther. 13, 444–453 (2014).
34. Aich, J., Mabaliwajjara, U., Ahmad, T., Agrawal, A. & Ghosh, B. Loss-of-function of inositol polyphosphate-4-phosphatase reversibly increases the severity of allergic airway inflammation. Nat. Commun. 3, 877 (2012).
35. Yao, Z. et al. TGF-beta1-induced siRNA-mediated selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. USA 107, 15535–15540 (2010).
36. Huang, Q. et al. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J. Exp. Clin. Cancer Res 38, 129 (2019).
37. Cao, S. et al. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC. J. Exp. Clin. Cancer Res 37, 220 (2018).
38. Li, L. et al. Methformin sensitizes EGFR-TK1-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin. Cancer Res. 20, 2714–2726 (2014).